During an 18‐month course of automated insulin delivery treatment, children aged 2 to 6 years achieve and maintain a higher time in tight range

Abstract

AbstractAimsTo investigate whether the positive effects on glycaemic outcomes of 3‐month automated insulin delivery (AID) achieved in 2‐ to 6‐year‐old children endure over an extended duration and how AID treatment affects time in tight range (TITR), defined as 3.9–7.8 mmol/L.Research Design and MethodsWe analysed 18 months of follow‐up data from a non‐randomized, prospective, single‐arm clinical trial (n = 35) conducted between 2021 and 2023. The main outcome measures were changes in time in range (TIR), glycated haemoglobin (HbA1c), time above range (TAR), TITR, and mean sensor glucose (SG) value during follow‐up visits (at 0, 6, 12 and 18 months). The MiniMed 780G AID system in SmartGuard Mode was used for 18 months. Parental diabetes distress was evaluated at 3 and 18 months with the validated Problem Areas in Diabetes—Parent, revised (PAID‐PR) survey.ResultsBetween 0 and 6 months, TIR and TITR increased, and HbA1c, mean SG value and TAR decreased significantly (p < 0.001); the favourable effect persisted through 18 months of follow‐up. Between 3 and 18 months, PAID‐PR score declined significantly (0 months: mean score 37.5; 3 months: mean score 28.6 [p = 0.06]; 18 months: mean score 24.6 [p < 0.001]).ConclusionsTreatment with AID significantly increased TITR and TIR in young children. The positive effect of AID on glycaemic control observed after 6 months persisted throughout the 18 months of follow‐up. Similarly, parental diabetes distress remained reduced during 18 months follow‐up. These findings are reassuring and suggest that AID treatment improves glycaemic control and reduces parental diabetes distress in young children over an extended 18‐month follow‐up.